Pfizer Inc. (PFE) Tax Rate: -3.54%
Is Pfizer Inc.’s tax rate high or low?
Pfizer Inc.'s tax rate of -3.54% is 76% above its 5-year average of -14.45%, near the high end of its 5-year range (-105.29%–9.58%).
82.01% below its 12-month average of -1.95%.
PFE Tax Rate Chart
PFE Average Tax Rate Chart
PFE Current vs Average Tax Rate Chart
PFE Tax Rate Metrics
TAX RATE
-3.54%
TAX RATE AVG TTM
-1.95%
TAX RATE AVG 3Y
-24.90%
TAX RATE AVG 5Y
-14.45%
TAX RATE AVG 10Y
-10.30%
TAX RATE AVG 15Y
0.15%
TAX RATE AVG 20Y
4.55%
CURRENT VS TTM AVG
-82.01%
CURRENT VS 3Y AVG
+85.78%
CURRENT VS 5Y AVG
+75.51%
CURRENT VS 10Y AVG
+65.63%
CURRENT VS 15Y AVG
-2411.84%
CURRENT VS 20Y AVG
-177.88%
Pfizer Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Tax Rate FAQ
- What is the tax rate for Pfizer Inc. (PFE)?
- The tax rate for PFE stock is -3.54%.
- Is Pfizer Inc.'s tax rate high or low?
- Pfizer Inc.'s tax rate of -3.54% is 76% above its 5-year average of -14.45%, near the high end of its 5-year range (-105.29%–9.58%).
- What is the TTM average tax rate for Pfizer Inc. (PFE)?
- The TTM average tax rate for PFE stock is -1.95%.
- What is the 3Y average tax rate for Pfizer Inc. (PFE)?
- The 3Y average tax rate for PFE stock is -24.90%.
- What is the 5Y average tax rate for Pfizer Inc. (PFE)?
- The 5Y average tax rate for PFE stock is -14.45%.
- What is the 10Y average tax rate for Pfizer Inc. (PFE)?
- The 10Y average tax rate for PFE stock is -10.30%.
- What is the 15Y average tax rate for Pfizer Inc. (PFE)?
- The 15Y average tax rate for PFE stock is 0.15%.
- What is the 20Y average tax rate for Pfizer Inc. (PFE)?
- The 20Y average tax rate for PFE stock is 4.55%.
Pfizer Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | -3.54% |
| 2024-12-31 | -0.35% |
| 2023-12-31 | -105.29% |
| 2022-12-31 | 9.58% |
| 2021-12-31 | 7.62% |
| 2020-12-31 | 5.26% |
| 2019-12-31 | 5.38% |
| 2018-12-31 | 5.94% |
| 2017-12-31 | -73.53% |
| 2016-12-31 | 13.44% |
| 2015-12-31 | 22.20% |
| 2014-12-31 | 25.50% |
| 2013-12-31 | 27.40% |
| 2012-12-31 | 19.76% |
| 2011-12-31 | 31.54% |
| 2010-12-31 | 11.54% |
| 2009-12-31 | 20.29% |
| 2008-12-31 | 16.97% |
| 2007-12-31 | 11.03% |
| 2006-12-31 | 15.29% |
| 2005-12-31 | 29.43% |
| 2004-12-31 | 19.03% |
| 2003-12-31 | 49.68% |
| 2002-12-31 | 22.12% |
| 2001-12-31 | 24.79% |
| 2000-12-31 | 35.53% |
| 1999-12-31 | 28.00% |
| 1998-12-31 | -24.77% |
| 1997-12-31 | 28.10% |
| 1996-12-31 | 31.06% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla